 Latent Tuberculosis
"Latent Tuberculosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.
| Descriptor ID |
D055985
|
| MeSH Number(s) |
C01.252.410.040.552.846.122
|
| Concept/Terms |
Latent Tuberculosis- Latent Tuberculosis
- Latent Tuberculoses
- Tuberculoses, Latent
- Tuberculosis, Latent
- Latent Tuberculosis Infection
- Infection, Latent Tuberculosis
- Infections, Latent Tuberculosis
- Latent Tuberculosis Infections
- Tuberculosis Infection, Latent
- Tuberculosis Infections, Latent
|
Below are MeSH descriptors whose meaning is more general than "Latent Tuberculosis".
Below are MeSH descriptors whose meaning is more specific than "Latent Tuberculosis".
This graph shows the total number of publications written about "Latent Tuberculosis" by people in this website by year, and whether "Latent Tuberculosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 | | 2010 | 3 | 0 | 3 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 1 | 3 | | 2016 | 4 | 2 | 6 | | 2017 | 1 | 2 | 3 | | 2018 | 5 | 1 | 6 | | 2019 | 1 | 2 | 3 | | 2020 | 8 | 0 | 8 | | 2021 | 5 | 0 | 5 | | 2022 | 1 | 0 | 1 | | 2023 | 4 | 0 | 4 | | 2024 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Latent Tuberculosis" by people in Profiles.
-
Salindri AD, Auld SC, Gujral UP, Urbina EM, Andrews JR, Huaman MA, Magee MJ. Tuberculosis infection and hypertension: prevalence estimates from the US National Health and Nutrition Examination Survey. BMJ Open. 2024 03 12; 14(3):e075176.
-
Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PP, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial. PLoS Med. 2024 Feb; 21(2):e1004356.
-
Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States. Ann Am Thorac Soc. 2023 09; 20(9):1258-1266.
-
Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Cayl? JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 06 16; 76(12):2090-2097.
-
Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, Cayla JA, Chen M, Feng PJ, Moro RN, Holland DP, Martinson N, Millet JP, Miro JM, Belknap R. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 06; 129:107173.
-
Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790.
-
Winglee K, Hill AN, Belknap R, Stout JE, Ayers TL. Variability of interferon-? release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clin Microbiol Infect. 2022 Jul; 28(7):1023.e1-1023.e7.
-
Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. Clin Infect Dis. 2021 11 02; 73(9):e3555-e3562.
-
Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis. 2021 11 02; 73(9):e3459-e3467.
-
Pettit AC, Stout JE, Belknap R, Benson CA, S?raphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS. Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021 10 05; 73(7):e2278-e2284.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|